Acute myeloid leukemia (AML) is a heterogeneous disease resulting in different outcomes for patients after chemotherapy treatment. The variation in prognosis of AML patients depends on multiple intrinsic factors, including karyotype and molecular alterations as well as the expression of stem cell genes. MicroRNAs (miRNAs) have emerged as epigenetic regulators affecting both normal as well as pathological processes by regulating protein expression. [...],
Department of Hematology

de Leeuw, D.C, Verhagen, H.J.M.P, Denkers, F, Kavelaars, F.G, Valk, P.J.M, Schuurhuis, G.J, … Smit, L. (2016). MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia. Leukemia, 30(3), 742–746. doi:10.1038/leu.2015.160